Skip to main content
. 2020 Feb 10;20:105. doi: 10.1186/s12885-020-6572-6

Table 3.

Main outcome variables

Author Reported overall survival (yes/no) Separately reported overall survival on mono- and bidirectional treated patients yes/no (number of patients) PFS reported (yes/no) QoL reported (yes/no)
Alyami et al. [27] No No No No
Demtröder et al. [28] Yes (from 1st PIPAC) No No No
Falkenstein et al. [29] Yes (from 1st PIPAC) No No No
Graversen et al. [30] Yes (from 1st PIPAC)a Yes (n = 5) No No
Hilal et al. [31] No No No No
Khomyakov et al. [24] Yes (not clear from when) Yes (n = 31)c No No
Khosrawipour et al. [32] Yes (from 1st PIPAC) No No No
Nadiradze et al. [33] Yes (from 1st PIPAC) No No No
Reymond et al. [34]a Yes (from 1st PIPAC)b Yes (n = 3) No No
Robella et al. [26] No No No Yes
Farinha et al. [35] No No No Yes
Hübner et al. [36] No No No No

PFS progression free survival, QoL Quality of life

aSurvival also reported from the time of primary tumor resection, and from the time of the PM diagnosis

bSurvival also reported from the time of diagnosis (of either the primary cancer or of PM)

cAll patients treated bidirectionally